nlink
glycoprotein
er
glucosemimick
iminosugar
galactosemimick
iminosugar
erassoci
degrad
dengu
viru
antivir
mechan
action
iminosugar
mani
envelop
virus
includ
dengu
viru
denv
hiv
influenza
hepat
c
viru
believ
mediat
induc
misfold
viral
nlink
glycoprotein
inhibit
host
endoplasm
reticulumresid
enzym
lead
reduc
secret
andor
infect
virion
henc
lower
viral
titr
vitro
vivo
free
oligosaccharid
analysi
iminosugartr
cell
show
antivir
activ
correl
product
monoand
triglucosyl
sugar
indic
inhibit
er
demonstr
glucosemimick
iminosugar
inhibit
isol
glycoprotein
glycolipid
process
enzym
inhibit
also
occur
primari
cell
treat
drug
galactosemimick
iminosugar
test
inhibit
glycoprotein
process
inhibit
glycolipid
process
antivir
denv
comparison
antivir
activ
glucosemimet
iminosugar
inhibit
endoplasm
reticulumresid
glycolipid
process
demonstr
inhibit
respons
iminosugar
antivir
activ
denv
monograph
review
investig
mani
research
mechan
action
iminosugar
contribut
current
understand
mechan
optimis
clinic
deliveri
iminosugar
effect
iminosugar
enzym
glucosidas
induct
er
stress
viral
receptor
also
put
context
data
suggest
inhibit
result
inhibit
releas
viru
primari
antivir
mechan
action
iminosugar
denv
transmit
femal
aed
mosquito
dengu
viru
denv
infect
almost
million
peopl
year
grow
global
health
problem
despit
licensur
first
dengu
vaccin
cydtdv
develop
clinic
test
novel
antivir
therapi
dengu
viru
remain
imper
display
differenti
efficaci
four
dengu
serotyp
licenc
peopl
nonor
lowendem
area
eg
travel
militari
personnel
due
reduc
efficaci
seroneg
recipi
increas
risk
antibodydepend
enchant
ade
licenc
antivir
therapi
treat
dengu
diseas
thu
still
vital
import
reduc
morbid
mortal
inhibit
biosynthesi
nlink
oligosaccharid
involv
glycosyl
glycoprotein
process
target
antivir
approach
number
decad
nlink
glycan
ad
protein
specif
amino
acid
sequenc
initi
addit
glc
man
glcnac
glc
glucos
man
mannos
glcnac
nacetyl
glucosamin
fig
precursor
oligosaccharid
transfer
glycoprotein
carbohydr
chain
subject
varieti
process
reaction
includ
remov
follow
transloc
newli
transcrib
peptid
er
preassembl
precursor
oligosaccharid
consist
glucos
glc
mannos
man
nacetylglucosamin
glcnac
residu
glc
man
glcnac
transfer
nascent
polypeptid
stepwis
remov
first
outer
glucos
residu
glui
next
two
glucos
residu
ii
gluii
occur
lectin
chaperon
calnexin
calreticulin
bind
monoglucosyl
oligosaccharid
intermedi
glc
man
glcnac
slow
glycoprotein
progress
er
allow
correct
fold
udpglucos
glycoprotein
glycoslytransferas
uggt
detect
misfold
protein
reglucosyl
oligosaccharid
allow
repeat
interact
calnexin
fold
chaperon
enzym
calnexin
cycl
correctli
fold
protein
bud
er
transport
golgi
process
altern
undergo
addit
process
er
degradationenhanc
ilik
protein
edem
er
mannosidas
target
degrad
free
oligosaccharid
fo
gener
protein
nglycosyl
mammalian
cell
specif
speci
detect
hplc
cell
lysat
exampl
inhibit
gluii
result
monoglucosyl
glycoprotein
trim
glycan
precursor
mannosidas
recognit
glycoprotein
termin
misfold
glc
man
glcnac
fo
speci
cleav
peptid
erassoci
degrad
erad
case
inhibit
glui
shown
glc
man
glcnac
fo
speci
detect
adapt
addit
sugar
residu
endoplasm
reticulum
er
golgi
produc
typic
highmannos
hybrid
complex
type
oligosaccharid
glycan
play
specif
role
glycoprotein
fold
calnexincalreticulin
cycl
glui
ii
gluii
sequenti
trim
termin
glucos
precursor
oligosaccharid
result
monoglucosyl
glc
man
glcnac
bound
calnexin
interact
variou
protein
disulphid
isomeras
chaperon
glycoprotein
chanc
fold
correctli
held
er
progress
golgi
glycoprotein
eventu
play
role
viral
life
cycl
incorpor
new
virion
host
cell
glycosyl
process
requir
virus
express
glycoprotein
viru
identifi
encod
enzym
requir
biosynthesi
nlink
oligosaccharid
denv
possess
four
nlink
glycoprotein
envelop
premembran
nonstructur
protein
nonstructur
protein
iminosugar
name
due
resembl
monosaccharid
differ
ring
oxygen
replac
nitrogen
atom
replac
oxygen
reduc
iminosugar
suscept
cleavag
glucosidas
allow
derivat
nitrogen
atom
sever
iminosugar
inhibitor
cellular
glycosidas
enzym
nlink
glycan
process
pathway
deoxynojirimycin
dnj
first
shown
inhibit
format
complex
glycan
saccharomyc
cerevisia
inhibit
action
er
glui
gluii
earliest
enzym
nglycan
process
pathway
fig
subsequ
antivir
potenti
realis
castanospermin
nalkyl
deriv
dnj
shown
inhibit
hiv
er
chaperon
bip
heat
shock
protein
assist
protein
fold
carbohydrateindepend
manner
unlik
calnexincalreticulin
denv
e
protein
bind
bip
infect
cell
knockdown
bip
calnexin
calreticulin
result
reduc
product
infecti
viru
indic
chaperon
play
role
fold
assembl
dengu
protein
interestingli
bip
propos
act
attach
entri
receptor
denv
certain
cell
despit
chaperon
redund
er
inhibitor
first
shown
antivir
effect
denv
courageot
et
al
via
mechan
affect
viral
protein
synthesi
appear
reduc
prme
heterodim
format
stabil
conclud
format
properli
fold
denv
envelop
complex
requir
lectin
chaperon
pathway
sinc
mani
studi
shown
iminosugar
antivir
denv
summaris
publish
antivir
data
iminosugar
denv
vitro
tabl
vivo
tabl
highlight
progress
field
mani
differ
dnjderiv
bicycl
iminosugar
demonstr
antivir
effect
denv
number
studi
sinc
last
review
field
tripl
particular
progress
vivo
studi
import
step
progress
clinic
trial
two
lead
therapeut
candid
iminosugar
methoxynnonyl
deoxynojirimycin
mondnj
celgosivir
prodrug
castanospermin
progress
phase
ib
clinic
trial
respect
appear
safe
seriou
advers
event
report
celgosivir
bucast
butyl
prodrug
cleav
cell
produc
castanospermin
bicycl
iminosugar
submicromolar
activ
denv
vitro
vivo
mous
model
result
combin
encourag
preclin
pharmacolog
result
human
safeti
data
obtain
clinic
trial
celgosivir
hiv
hepat
c
viru
hcv
modest
antivir
effect
support
phase
randomis
doubleblind
placebocontrol
clinic
trial
adult
dengu
patient
celaden
trial
recruit
patient
fever
less
h
dose
celgosivir
initi
mg
load
dose
follow
mg
everi
h
total
nine
dose
studi
fail
show
decreas
fever
durat
viral
load
author
subsequ
investig
optimis
dose
give
higher
minimum
concentr
perform
phase
iia
clinic
trial
fourtim
daili
treatment
first
trial
rapid
clearanc
antigen
observ
patient
treat
celgosivir
compar
placebo
effect
promin
patient
secondari
dengu
infect
also
highlight
possibl
therapeut
differ
patient
primari
secondari
infect
indic
futur
trial
power
investig
ade
anti
antibodi
mice
n
pb
pbscontain
perl
death
day
pi
nonsignific
reduct
liver
spleen
viral
titr
mgkgday
effect
surviv
nonsignific
reduct
liver
spleen
viru
titr
mgkgday
surviv
mgkgday
surviv
signific
viral
load
reduct
liver
small
intestin
serum
spleen
day
pi
mgkgday
encapsul
perl
surviv
encapsul
provid
dose
abl
increas
surviv
nonsignific
reduct
liver
spleen
viral
titr
mondnj
develop
potent
yet
similarli
nontox
deriv
nbutyldnj
nbdnj
alkyl
chain
elong
oxygen
demonstr
potent
vivo
antivir
effect
nbdnj
dengu
viru
mondnj
antivir
activ
rang
virus
vitro
vivo
efficaci
anim
model
dengu
influenza
viru
phase
singleascend
dose
clinic
trial
mondnj
human
recent
complet
volunt
receiv
singl
oral
dose
rang
mg
seriou
advers
event
report
even
highest
dose
mg
overal
well
toler
multipleascend
dose
studi
current
underway
prepar
efficaci
test
denv
human
sever
member
class
small
molecul
known
iminosugar
broadspectrum
antivir
activ
vitro
dna
rna
virus
virus
bud
either
er
plasma
membran
howev
current
possibl
predict
nglycan
may
util
engag
calnexin
cycl
protein
may
depend
proper
fold
degre
nglycosyl
number
disulphid
bond
complex
fold
requir
oligomeris
cotransl
cleavag
event
amongst
factor
propos
contribut
sensit
iminosugar
ongo
futur
studi
continu
elucid
relationship
glucosidas
inhibit
antivir
action
form
paper
hammond
braakman
heleniu
year
ago
role
calnexin
cycl
specif
monoglucosyl
glycan
play
correct
glycoprotein
fold
critic
develop
percept
iminosugar
antivir
research
last
decad
significantli
progress
understand
mechan
fulli
elucid
iminosugar
known
inhibit
enzym
trim
termin
glucos
residu
nascent
glycoprotein
er
control
interact
calnexin
cycl
henc
proper
glycoprotein
fold
transport
evid
suggest
prevent
appropri
fold
viral
glycoprotein
iminosugar
prevent
format
infecti
viral
particl
understand
mechan
antivir
action
iminosugar
progress
last
decad
shall
put
new
find
context
within
field
experi
publish
clarifi
treatment
denvinfect
cell
rang
iminosugar
result
reduc
secret
denv
rather
reduct
virion
infect
iminosugar
demonstr
antivir
activ
four
serotyp
denv
supernat
iminosugartr
denvinfect
primari
human
macrophag
assay
infecti
viru
plaqu
assay
total
viru
product
qrtpcr
denv
rna
level
viru
decreas
concomitantli
consist
er
inhibit
result
suffici
misfold
viral
glycoprotein
target
degrad
reduc
secret
viru
howev
reduc
secret
outcom
iminosugar
treatment
virus
case
hiv
iminosugar
affect
infect
greater
degre
secret
iminosugar
treatment
alter
glycosyl
result
modest
reduct
viru
releas
infect
cell
strongli
impair
viral
entri
stage
post
possibl
predict
whether
iminosugar
treatment
result
reduc
virion
infect
alon
also
reduc
secret
determin
virusbyviru
basi
differenti
effect
iminosugar
iminosugar
sixmemb
ring
broadspectrum
antivir
activ
virus
infect
human
secret
infect
seen
differ
virus
may
also
compound
cell
type
specif
babi
hamster
kidney
bhk
cell
nnonyldnj
nndnj
reduc
denv
rna
replic
addit
effect
denv
glycoprotein
unlik
observ
relat
virus
bovin
viral
diarrhoea
viru
bvdv
hcv
absenc
direct
effect
rna
replic
shown
addit
research
monitor
effect
iminosugar
denv
replic
relev
primari
cell
would
valuabl
clarifi
rel
contribut
inhibit
viral
rna
replic
glycoprotein
fold
overal
antivir
effect
observ
find
two
document
live
individu
genet
defici
glui
provid
support
treatment
viral
infect
inhibitor
two
children
seem
resist
infect
envelop
virus
children
histori
viral
diseas
despit
substanti
hypogammaglobulinemia
produc
immun
respons
live
viral
vaccin
still
produc
normal
respons
protein
polysaccharid
conjug
proteinpolysaccharid
immunogen
cell
cultur
children
shown
express
gluii
equal
suscept
infect
hiv
comparison
control
cell
howev
virion
produc
less
infecti
produc
glui
gene
recompl
back
display
similarli
antivir
phenotyp
manifest
initi
stage
cell
infect
monocytederiv
macrophag
cultur
patient
either
weakli
product
infect
influenza
viru
less
infecti
viru
produc
cell
phenotyp
consist
hypothesi
inhibit
glui
suffici
antivir
activ
convinc
evid
show
inhibit
correl
antivir
activ
denv
much
depend
quantif
monoand
triglucosyl
free
oligosaccharid
fo
speci
gener
specif
fo
end
product
protein
misfold
give
measur
access
iminosugar
er
combin
er
inhibit
activ
consequ
inhibit
er
gluii
monoglucosyl
glycoprotein
produc
fig
trim
glycan
precursor
mannosidas
recognit
glycoprotein
termin
misfold
glc
man
glcnac
glc
man
glcnac
fo
speci
cleav
peptid
erassoci
degrad
erad
case
inhibit
er
glui
similar
process
produc
glc
man
glcnac
speci
thu
presenc
speci
fo
correl
success
inhibit
respect
cellular
addit
nbdnj
nndnj
mondnj
celgosivir
macrophag
led
gener
monoand
triglucosyl
fo
speci
demonstr
inhibit
degre
inhibit
gluii
ie
gener
glc
man
glcnac
fo
plot
antivir
activ
rang
iminosugar
concentr
clear
correl
observ
two
paramet
fig
consist
gluii
inhibit
suffici
achiev
antivir
effect
interact
dengu
e
er
chaperon
facilit
denv
product
ideal
confirm
block
viral
glycoprotein
entri
er
calnexin
qualiti
control
cycl
result
format
misfold
viral
glycoprotein
subsequ
antivir
effect
demonstr
iminosugar
treatment
denvinfect
cell
result
misfold
denv
glycoprotein
would
import
three
studi
monitor
effect
iminosugar
denv
glycoprotein
fold
secret
document
tabl
castanospermin
treatment
denvinfect
cell
reduc
level
immunoprecipit
e
compar
untreat
cell
conformationsensit
monoclon
antibodi
use
amount
e
coprecipit
prm
untreat
cell
demonstr
iminosugar
decreas
format
prme
heterodim
inhibit
glucosidas
affect
correct
fold
denv
e
system
studi
monitor
effect
iminosugar
fold
denv
glycoprotein
could
expand
util
larger
panel
monoclon
antibodi
recognis
conformationdepend
independ
epitop
four
denv
glycoprotein
perform
heavili
studi
hiv
mani
valid
reagent
avail
studi
effect
nbdnj
fold
demonstr
interact
calnexincalreticulin
pathway
critic
correct
fold
loop
hiv
block
entri
fold
pathway
result
conform
defect
region
recent
studi
took
observ
step
assess
region
fold
use
monoclon
antibodi
conform
epitop
combin
mathemat
model
show
misfold
portion
suffici
produc
amplifi
effect
infect
sg
spiro
unpublish
result
addit
studi
compar
level
express
denv
glycoprotein
state
fold
presenc
absenc
iminosugar
clarifi
whether
iminosugar
induc
misfold
degrad
denv
glycoprotein
least
two
outcom
inhibit
prevent
product
monoglucosyl
glycan
block
glycoprotein
bind
calnexincalreticulin
describ
wu
et
al
secondli
retain
termin
glucos
block
access
enzym
arm
glycan
theoret
prevent
format
complex
glycan
hypothesi
glucosidas
inhibitor
may
antivir
due
absenc
complex
sugar
basi
origin
studi
iminosugar
virus
cell
activ
golgi
endomannosidas
partial
salvag
howev
activ
endomannosidas
highli
cell
line
depend
exampl
cell
human
hepatoma
cell
line
express
high
level
endomannosidas
chines
hamster
ovari
cho
madindarbi
canin
kidney
mdck
cell
detect
endomannosidas
activ
product
denv
prm
hyperglycosyl
glycan
demonstr
mobil
shift
viral
glycoprotein
electrophoresi
confirm
analys
glycan
structur
attach
specif
glycoprotein
sar
coronaviru
influenza
viru
though
yet
denv
glycoprotein
human
cell
activ
endomannosidas
import
vitro
experi
effect
glucosidas
inhibit
use
cell
line
express
endomannosidas
relev
interest
ascertain
whether
denv
glycoprotein
produc
presenc
iminosugar
bear
triglucosyl
glycan
glucos
mimet
surpris
iminosugar
inhibit
er
iminosugar
also
target
intestin
digest
enzym
includ
sucras
isomaltas
interact
consist
mildmoder
revers
gastrointestin
symptom
includ
flatul
diarrhoea
seen
particip
celgosivir
nbdnj
clinic
trial
combin
low
sucros
starch
high
glucos
diet
antidiarrhoea
agent
control
symptom
interest
iminosugar
inhibit
intestin
use
benefit
patient
noninsulin
depend
diabet
market
prevent
digest
carbohydr
lower
degre
postprandi
hyperglycemia
establish
greater
glycem
control
diabet
mellitu
type
long
alkyl
chain
iminosugar
nndnj
galactos
mimet
nndeoxygalactonojirimycin
nndgj
mediat
antivir
effect
bvdv
hcv
via
inhibit
viral
ion
channel
activ
manner
independ
inhibit
glucoserecognis
host
cell
enzym
antivir
mechan
action
evok
denv
exist
dengu
ion
channel
need
postul
well
inhibit
long
alkyl
chain
iminosugar
although
controversi
exist
literatur
studi
wong
et
al
suggest
neither
prm
protein
show
phactiv
ion
channel
activ
express
surfac
xenopu
oocyt
combin
observ
nndgj
antivir
denv
vitro
would
indic
unlik
mechan
action
case
denv
nbdnj
well
dnjand
dgjderiv
iminosugar
longer
alkyl
tail
also
inhibit
glucosylceramid
synthas
gc
glucosyltransferas
effect
depend
mimick
glucos
stereochemistri
mimick
substrat
gc
ceramid
comparison
antivir
activ
inhibit
glycolipid
process
use
glucos
galactos
analogu
iminosugar
recent
shown
antivir
activ
iminosugar
denv
function
inhibit
glycoprotein
process
rather
due
effect
gc
block
product
fold
viral
glycoprotein
alter
retent
time
er
lumen
follow
accumul
andor
increas
erad
accumul
misfold
denv
glycoprotein
induc
unfold
protein
respons
upr
cell
attempt
redress
imbal
homeostasi
denv
infect
alon
induc
regul
upr
pathway
human
monocyt
cell
stimul
bip
mrna
transcript
addit
celgosivir
appear
reduc
downstream
effector
mechan
upr
pathway
demonstr
reduc
phosphoryl
celgosivir
treatment
alon
presenc
denv
upregul
transcript
er
chaperon
promot
degrad
unfold
protein
clear
er
reduc
stress
taken
togeth
vasudevan
colleagu
suggest
denv
infect
presenc
celgosivir
characteris
reduc
er
stress
enhanc
surviv
modul
upr
induc
respons
increas
viral
protein
level
er
propos
therapeut
target
modul
receptor
import
denv
lifecycl
pathogenesi
addit
potenti
pathway
iminosugar
may
exert
antivir
effect
mani
host
protein
vital
denv
attach
uptak
signal
immun
respons
nlink
glycoprotein
thu
perturb
express
function
could
implic
viru
growth
effect
iminosugar
secret
differ
virus
effect
host
glycoprotein
predict
protein
specif
treatment
dnjderiv
alter
nlink
glycan
structur
angiotensin
iconvert
enzym
manner
affect
express
bind
sarscov
spike
glycoprotein
disrupt
abil
particip
viru
envelopetrigg
membran
fusion
host
glycoprotein
examin
specif
effect
iminosugar
express
function
number
challeng
lie
ahead
optimis
clinic
deliveri
iminosugar
pharmaceut
use
one
specif
difficulti
use
iminosugar
treat
dengu
diseas
broadli
applic
use
acut
viral
infect
short
window
avail
treatment
time
dengu
patient
present
healthcar
system
typic
may
fever
day
stage
h
viral
load
drop
immun
system
control
viral
replic
task
antivir
reduc
viral
load
window
requir
safe
fast
act
highli
potent
drug
consid
whether
iminosugar
could
administ
peopl
live
endem
set
present
fever
independ
differenti
diagnosi
dengu
therapeut
would
need
excel
safeti
profil
phase
singleascend
dose
trial
result
recent
releas
mondnj
promis
respect
howev
recruit
clinic
trial
test
safeti
pharmacokinet
mondnj
administ
multipl
ascend
dose
termin
busi
reason
march
challeng
relev
use
iminosugar
therapeut
number
acut
virus
treat
chronic
viral
diseas
present
differ
challeng
rapid
clearanc
iminosugar
vivo
make
reach
suffici
concentr
mediat
antivir
effect
specif
challeng
compound
follow
oral
administr
celgosivir
plasma
halflif
h
patient
similar
h
mice
given
singl
dose
mondnj
oral
mgkg
addit
iminosugar
gener
excret
rapidli
urin
clinic
trial
test
nbdnj
hiv
conclud
suffici
plasma
concentr
could
achiev
obtain
convinc
antivir
effect
effort
maximis
mean
trough
concentr
increas
chanc
success
test
celgosivir
efficaci
denv
coordin
next
celgosivir
trial
perform
pharmacokinet
model
propos
increas
number
dose
per
day
altern
approach
previous
shown
enhanc
antivir
activ
iminosugar
hiv
vitro
encapsul
compound
liposom
system
use
clinic
mediat
intracellular
deliveri
anticanc
antifung
treatment
test
vivo
denv
ade
mous
model
liposomemedi
deliveri
nbdnj
comparison
free
nbdnj
result
reduct
dose
drug
requir
enhanc
anim
surviv
although
promis
approach
specif
formul
liposom
test
studi
costli
suffici
stabl
liposomemedi
deliveri
investig
avail
iminosugar
gener
low
toxic
make
optimis
pharmacokinet
dose
regimen
current
promis
approach
optimis
clinic
iminosugar
deliveri
er
glucosidas
control
glycan
process
viral
host
cellular
glycoprotein
would
necessarili
predict
inhibit
er
glucosidas
select
suppress
viral
replic
yet
anim
least
therapeut
window
clearli
exist
iminosugar
antivir
well
toler
least
acut
treatment
number
possibl
explan
exist
dichotomi
experi
need
perform
determin
rel
contribut
virus
infect
cell
protein
predomin
protein
synthesis
henc
may
suscept
inhibit
er
glucosidas
addit
denv
virion
compris
close
pack
repetit
coordin
interact
e
prm
protein
may
increas
virion
suscept
perturb
interestingli
case
hiv
littl
protein
misfold
requir
affect
virion
infect
sg
spiro
unpublish
result
proport
misfold
presenc
nbdnj
model
hiv
infect
shown
highli
sensit
misfold
small
proport
total
suggest
amplif
effect
may
contribut
select
iminosugar
virus
host
background
histor
find
highlight
advanc
made
last
decad
understand
mechan
antivir
activ
iminosugar
denv
gener
accept
antivir
mechan
er
glucosidas
inhibitor
inhibit
glui
andor
gluii
prevent
remov
termin
glucos
moieti
nlink
glycan
result
misfold
retent
glycoprotein
er
ultim
degrad
via
erad
support
number
piec
evid
includ
observ
iminosugar
induc
electrophoret
mobil
shift
viral
glycoprotein
well
structur
chang
nlink
glycan
measur
fo
consist
glui
gluii
inhibit
correl
antivir
effect
substrat
flux
along
nlink
glycosyl
pathway
make
correl
key
enzym
antivir
effect
complex
though
glui
gluii
target
iminosugar
slower
remov
third
glucos
residu
gluii
even
though
iminosugar
bind
approxim
tenfold
avidli
glui
sensit
inhibit
iminosugar
result
inhibit
enzym
viral
envelop
glycoprotein
interact
er
chaperon
calnexin
calreticulin
prevent
correct
glycoprotein
fold
oligomer
assembl
infecti
virion
unit
conclus
multipl
studi
also
allow
us
highlight
area
mechan
action
iminosugar
denv
could
understood
greater
molecular
detail
use
panel
antidenv
glycoprotein
monoclon
antibodi
known
specif
bind
denv
glycoprotein
produc
presenc
iminosugar
potenti
enabl
map
region
iminosugarinduc
misfold
may
inform
understand
exampl
e
dimer
degre
locat
misfold
may
protein
depend
potenti
even
straindepend
differ
use
iminosugar
galactos
stereochemistri
dgj
compound
allow
conclus
antivir
effect
piperidin
iminosugar
monocyl
iminosugar
iminopyranos
structur
denv
observ
macrophag
mediat
effect
enzym
glycolipid
pathway
develop
select
er
inhibitor
would
allow
confirm
er
inhibit
enzym
respons
antivir
effect
iminosugar
avoid
gastrointestin
side
effect
due
inhibit
intestin
glucosidas
recent
publish
structur
gluii
alon
complex
mondnj
castanospermin
see
chap
provid
opportun
ration
drug
design
greater
understand
biochem
detail
underli
inhibit
host
enzym
